Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Cancer victims set to benefit as NHS changes

Jeremy Laurance
Wednesday 31 March 1999 18:02 EST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

WOMEN WITH ovarian cancer are likely to be among the first beneficiaries of a series of changes to the NHS.

Yesterday marked the end of GP fundholding and the beginning of a huge transfer of power and resources from hospitals to family doctors, backed by a series of measures designed to increase quality in the NHS.

The most important of these is the National Institute of Clinical Excellence (Nice), a national agency introduced to appraise new treatments and ensure those that are valuable are spread around the NHS. Taxol, the drug for advanced ovarian cancer that has been the focus of allegations of "postcode prescribing", is expected to be one of the first to be considered by the agency.

Ministers have said they expect Nice to give "a big nod" to Taxol, which some health authorities have refused to supply because of its pounds 6,000- a-year cost per patient. The drug has been shown in trials to extend survival by 12 months.

Nice, which is expected to issue its first guidance in the autumn, will look at the cost as well as the effectiveness of new treatments and surgical techniques and is seen by doctors as a tool for rationing NHS care.

Quality of care will also be monitored by the new Commission for Health Improvement, an NHS inspectorate that will ensure hospitals are implementing a system of "clinical governance" - checking standards of care and identifying poor doctors.

The biggest change is the abolition of GP fundholding and its replacement by 481 "primary care groups" - local groups of GPs and nurses - who will have responsibility for spending 90 per cent of NHS resources.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in